EndoGene.Bio's EIC Accelerator Plan for Endometriosis Profiling

16 November 20261,826 words10 min

Endometriosis affects an estimated 190 million women of reproductive age, and the average time to diagnosis is between 4 and 12 years, according to the World Health Organization. Imaging can support the diagnosis, but confirmation can still require surgery, and no existing treatment cures the disease. EndoGene.Bio, a Paris company founded in 2022, wants to replace the tissue sample with something patients shed every month: menstrual blood.

On 16 November 2026 the European Innovation Council announced 35 companies selected for EIC Accelerator support from the round that combined the 6 May and 8 July 2026 cut-offs. EndoGene.Bio is on the list with PRECISE-U, short for "PRECIsion Stratification Engine for Uterine diseases", recommended for blended finance, meaning a grant plus a possible equity investment by the EIC Fund. The list states that selection "does not constitute a formal commitment for funding". This article sets out what the project promises and what can already be checked, on the day the selection was published.

35 of 453Full applications selected in the round, per the EIC
81%Accuracy of the company's methylation model in a 42-woman pilot
2022Year the company started trading, per the French register

Company file

Legal entity
EndoGene.Bio, société par actions simplifiée, SIREN 910 384 999
Started
Activity began 21 January 2022; registered 15 February 2022
Sites
Registered office in Paris 1er; laboratory establishment at Genopole, Évry-Courcouronnes, opened April 2022
Leadership
María Teresa Pérez Zaballos, president and co-founder; Cristina Fernández Molina, co-founder and head of science
Staff
6 to 9 employees in the 2024 size band of the official company directory
Public support
Innov'up funding from Bpifrance (July 2024) and an i-Lab prize (2024), per Genopole
EIC project
PRECISE-U, selected for blended finance; no grant agreement published yet

A biopsy that arrives every month

The company's website describes it as a biological data platform for uterine health that turns menstrual blood into "a non-invasive biopsy". It names two components: Endoprofile Gateway, a collection and laboratory process the site calls patented, and Endoprofile Engine, which models how the disease starts, progresses and responds to treatment at the molecular level. It sells into four uses: patient stratification for clinical trials, drug repositioning, target discovery and, last on the list, non-invasive diagnostics. The site names no patent number, and sources reviewed on 16 November 2026 did not identify a published patent under the company's name.

The science behind the pitch is in a paper. In Communications Medicine, a Nature Portfolio journal, the company and clinicians from Hospital Clínic Barcelona and the Complejo Hospitalario Universitario Insular Materno Infantil de Canarias published a whole-genome methylation study of stem cells isolated directly from menstrual blood, without culturing them. The paper was received on 12 September 2025, accepted on 24 April 2026 and published on 16 May 2026, after a bioRxiv preprint in July 2025. In 19 women with endometriosis and 23 controls, a machine-learning model built on four methylated regions reached 81% accuracy, 79% sensitivity and 83% specificity.

The evidence

81% accuracy in a 42-woman pilot, tested within the same group

Best model from 19 women with endometriosis and 23 controls, built on four methylated regions and evaluated by leave-one-out cross-validation; no independent cohort was tested.

Tiniakou et al., Communications Medicine, 16 May 2026 (PMC13434008).

What the pilot does not show

The model was tested by leave-one-out cross-validation within the same 42 women, and no independent patient cohort was used, according to the full text in PubMed Central. The authors list the limits themselves: a small sample, low yields of sorted cells, possible undiagnosed disease among controls, and participants who were predominantly of White European ancestry. Seven authors are employees of the company and one is its chief executive, and the study was funded by EndoGene.Bio with grant support from Bpifrance, the paper states.

A second line of work concerns treatment, not diagnosis. A bioRxiv preprint posted in December 2025, which has not been peer reviewed, combined public single-cell datasets with drug perturbation profiles and reported different predicted drug responses between patients and between cell types. Femtech Insider reported on 8 January 2026 that the drug-response signatures found in lesions were also detectable in endometrial stromal cells of the kind shed during menstruation. That link between a lesion and a menstrual sample is the premise of a stratification engine, and it rests so far on that preprint.

A small company with a laboratory at Genopole

The French register gives a modest picture. The official company directory lists EndoGene.Bio as an active SAS, classed under research and development in other physical and natural sciences (NAF code 72.19Z), with María Teresa Pérez Zaballos as president and a second establishment at Genopole in Évry-Courcouronnes. Notices in the BODACC, France's official gazette of company notices, record two capital increases in 2022, to €2,914.07 in August and €3,130.93 in December, and a change in management and a capital reduction notice in December 2023. Accounts for each year from 2022 to 2025 were filed, the last on 8 September 2026, each with a confidentiality declaration, so no revenue, loss or equity figure is public.

The company's funding history is thin on primary sources. A Genopole press release of 3 October 2024 says EndoGene.Bio won Innov'up funding from Bpifrance in July 2024 and an i-Lab prize, a state-funded competition operated by Bpifrance with awards of up to €600,000, for a project called Medipred that aimed to predict treatment response from epigenetic markers in menstrual cells. The release does not give the amount of either award. The Entrepreneurs First portfolio lists the company at the pre-seed stage. Sources reviewed on 16 November 2026 show no priced funding round announced by the company, and no EIC Fund investment.

The record

From a 2022 start-up to an EIC selection in four years

Register notices, a Genopole release, two preprints and one peer-reviewed paper; the 2026 accelerator places are listed by the company and not confirmed by the programmes.

  1. Jan 2022Company startsEndoGene.Bio SAS begins activity on 21 January 2022 and is registered in Paris on 15 February
  2. Apr 2022Genopole siteA second establishment opens at Genopole in Évry-Courcouronnes
  3. Dec 2022Capital increasesTwo capital increases in August and December take share capital to €3,130.93€3,130.93
  4. Jul 2024Innov'upInnov'up funding from Bpifrance, followed by an i-Lab prize in the 26th edition, per Genopole
  5. Jul 2025Pilot preprintThe 42-woman methylation study is posted on bioRxiv
  6. Dec 2025Drug-response preprintSingle-cell signatures of predicted drug response are posted on bioRxiv, not peer reviewed
  7. May 2026Peer-reviewed paperThe methylation study is published in Communications Medicine
  8. Jun to Sep 2026Accelerator placesLilly Gateway Labs, DayOne and a Sanofi Golden Ticket, as listed on the company websiteCompany claim
  9. Nov 2026EIC selectionPRECISE-U is one of 35 projects selected for EIC Accelerator support, recommended for blended finance

BODACC; Annuaire des entreprises; Genopole, 3 October 2024; bioRxiv; Communications Medicine; EndoGene.Bio website; EIC, 16 November 2026.

Industry ties are announced, not documented. Femtech Insider reported on 21 October 2025 that the company won Insud Pharma's ChemoStart competition earlier that year and set up a research partnership with Exeltis, Insud's women's health business; pharmaphorum reported the Exeltis partnership on 17 October 2025. No terms are public. The company's website lists three 2026 programmes: a place in the first virtual Eli Lilly Gateway Labs cohort (2 June), selection for the DayOne Healthtech Innovation 2026 accelerator (24 August) and a Sanofi Golden Ticket at BioLabs (23 September). Sources reviewed on 16 November 2026 include no announcement of these by Lilly, DayOne or Sanofi.

Where PRECISE-U sits in the round

The EIC says the round drew 453 full applications, invited 88 companies to interview and selected 35, from 17 countries, with France among the three countries with the most companies. The proposed grant funding for all 35 is €84 million, and 32 of them will be assessed for EIC Fund equity of up to €10 million each. The announcement gives no amount per company, and grant agreements are expected within three months, so CORDIS lists no PRECISE-U project yet. The selection list's website column gives an unrelated consumer site, www.consumers-protection.org, for EndoGene.Bio and four other companies.

The competition

One of 35 companies picked from 453 full applications

The round combined the 6 May and 8 July 2026 cut-offs. A further 74 applications above the threshold received a Seal of Excellence for lack of funds.

EIC, 16 November 2026.

The policy frame is established. The European Commission's women's health page says the EU has invested over €2 billion in more than 1,000 women's health projects under Horizon 2020 and Horizon Europe, including EUmetriosis, a €7 million research initiative launched in January 2025. The EIC Accelerator has backed a direct rival before: CORDIS records €2,494,291 for TRANSCEND, a project by the British company PrecisionLife running from June 2025 to May 2027 to validate a non-invasive endometriosis risk test and guide repurposed drugs to disease subtypes.

What can be checked now

The EIC has not published a project summary for PRECISE-U, so the promise is what its title and the company say: a stratification engine for uterine diseases built on menstrual-blood data. The checklist below sets that against the public record.

  1. Selected for EIC Accelerator blended financeOn the listListed with PRECISE-U in the EIC announcement of 16 November 2026; not a formal funding commitment.
  2. Peer-reviewed proof of conceptPublished42-woman case-control study in Communications Medicine, May 2026.
  3. Validation in a larger cohortNot yet publicNamed as the next step by the company in coverage from October 2025 and June 2026; no registered trial or results found in sources reviewed on 16 November 2026.
  4. Stratification for drug developersCompany claimExeltis research partnership reported by trade press, terms undisclosed; treatment-response work only in a preprint.
  5. Signed grant and EIC Fund equityToo earlyGrant agreements are expected within three months of 16 November 2026; equity is decided separately by the EIC Fund.

What the company says

A non-invasive window on uterine biology from menstrual blood, a high-resolution atlas of disease-driving cell states, patented collection, and data that can stratify patients for trials, guide drug discovery and shorten diagnosis.

What the record shows

An active Paris SAS with 6 to 9 staff in 2024, a Genopole laboratory, a peer-reviewed pilot in 42 women with no independent test cohort, one unreviewed preprint, French public innovation awards, and an EIC selection without a published amount.

Verdict

EndoGene.Bio arrives at the EIC with more published science than many companies of its size: a peer-reviewed study whose authors spell out its limits. What the EIC selected, though, is the next stage, a stratification engine that pharmaceutical companies would pay for, and the evidence for that is a preprint, an undisclosed partnership and accelerator places listed on the company's own website. The test that matters is a larger, independent cohort, and sources reviewed on 16 November 2026 do not report one.

The reporting is based on publicly available sources, listed below.

Sources

  1. EIC, The European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026, with the list of selected companies for the May and July 2026 cut-offs
  2. Annuaire des entreprises, EndoGene.Bio, SIREN 910 384 999
  3. BODACC, notices for RCS 910 384 999, 2022 to 2026
  4. EndoGene.Bio, company website, read 16 November 2026
  5. Tiniakou et al., Whole genome methylation profiling of menstrual stem cells identifies novel biomarkers for endometriosis, Communications Medicine, 16 May 2026
  6. PubMed Central, full text of the Communications Medicine paper, PMC13434008
  7. bioRxiv, preprint of the methylation study, July 2025
  8. bioRxiv, Beyond one-size-fits-all: single-cell transcriptomic signatures predict drug efficacy and reveal responder subgroups in endometriosis, December 2025
  9. Femtech Insider, endogene.bio develops menstrual blood test for endometriosis detection, 21 October 2025
  10. Femtech Insider, endogene.bio research identifies molecular subtypes in endometriosis, 8 January 2026
  11. Femtech Insider, report on the published methylation study, 3 June 2026
  12. pharmaphorum, Could endometriosis be diagnosed with a simple test?, 17 October 2025
  13. Genopole, 4 startups accompagnées par Genopole, lauréates du concours d'innovation i-Lab, 3 October 2024
  14. Entrepreneurs First, portfolio entry for EndoGene.Bio
  15. World Health Organization, Endometriosis fact sheet
  16. European Commission, Research and innovation in women's health
  17. CORDIS, TRANSCEND project, PrecisionLife Ltd, grant agreement 101217760

Industry

HealthIn vitro diagnostics

AlsoHealthLife science tools

Focus
  • Molecular diagnostics
  • Analytical services
Technologies
  • DNA methylation analysis
  • Molecular biomarkers
  • Artificial intelligence
Keywords
  • Endometriosis
  • Women's health
  • Gynaecology
  • Menstrual blood
  • Patient stratification
  • Drug discovery
  • Single-cell analysis
  • Non-invasive diagnosis